Biomedical subjects
Publications and source records attributed to A M Sapugay.
Endometriosis is one of the most enigmatic and common diseases encountered by the gynecologist in the reproductive-age female. An estimated 10% of reproductive-age women and 25-35% of infertile women have this progressive disease which may result in significant morbidity.
OBJECTIVE: To determine if type II statistical errors (also known as beta errors) are a common problem in published clinical research. METHODS: Type II statistical errors occur when sample sizes are too small to show an effect of treatment, even when an effect truly exists. Searching the Medline data base, we identified ten meta-analyses published during 1986-1994 in the American Journal of Obstetrics and Gynecology, Obstetrics and Gynecology, and The Journal of Reproductive Medicine. Meta-analyses were used as sources of component or individual studies for the following reason: When small component studies have negative findings that differ from the overall conclusions of the meta-analysis, the component studies may have type II statistical errors. RESULTS: We found that only 6.5% (15 of 231) of component studies provided any documentation that power calculations to determine sample sizes had been done a priori (before) the research began. Thus, many of these component studies with findings of no treatment effect may have had type II errors because of too-small sample sizes. When stratifying the component studies by year of publication, we found that 7.9% (14 of 178) of studies published in the 1980s and 1990s had any documented evidence of a priori power calculations. In the 1960s and 1970s, only one of 53 component studies had documented evidence of power calculations. CONCLUSION: To ensure that truly effective treatments are introduced into clinical practice as quickly as possible, we believe that a priori power calculations should always be done in quantitative clinical research.
Experimental allergic encephalomyelitis (EAE) is an autoimmune inflammatory disease of the central nervous system (CNS). It is an animal model of post-infectious encephalomyelitis and multiple sclerosis (MS). Acute EAE is mediated by macrophages and by T helper 1 (Th1) lymphocytes directed against brain antigens. Inflammation in EAE could potentially be modified by prostaglandins (PG) secreted by blood monocytes (Mo) and brain glial cells. PGE elevates cAMP, which inhibits Mo function and selectively blocks secretion of cytokines by Th1 cells. In the present study, we found that a long-acting PGE1 analogue (LAPGE) inhibited clinical and histological EAE. Indomethacin (INDO) also suppressed active EAE. The combination of INDO plus LAPGE inhibited disease further, possibly by allowing LAPGE to function unopposed by immunostimulatory PG. EAE was suppressed when these agents were administered from the time of immunization or from the onset of clinical disease. The combination of INDO plus LAPGE also inhibited delayed-type hypersensitivity (DTH) reactions to myelin basic protein (MBP), and diminished in vitro lymphocyte responses to mitogens and MBP. PGE analogues and modifiers of arachidonate metabolism block autoimmune responses to brain antigens in vitro and in vivo, and may ameliorate inflammatory and autoimmune diseases of the brain and other organs.